Key points from article :
A US biotech company, Serina Therapeutics, has raised $5 million to support clinical trials for a new treatment for advanced Parkinson’s disease. Their drug, SER-252, uses a special delivery system to maintain steady dopamine levels and reduce movement problems like dyskinesia. The company plans to begin Phase 1 trials by late 2025.
SER-252 is a version of apomorphine, designed to deliver the drug steadily through the bloodstream. The goal is to give patients longer periods of relief from symptoms by avoiding the highs and lows caused by traditional treatments.
The treatment uses Serina’s POZ Platform, a water-soluble polymer that controls how and when drugs are released in the body. This system avoids common problems like immune reactions or drug buildup in tissues, which often limit long-term drug use.
POZ allows for fewer injections by keeping drug levels stable with weekly subcutaneous doses. It works with different types of drugs and can be delivered in several ways, including intravenously or intramuscularly.
Serina is based in Huntsville, Alabama, and recently merged with AgeX Therapeutics. This helped Serina gain public market access and expand its work on age-related diseases.
The funding reflects strong investor belief in SER-252’s potential. The treatment will enter first-in-human trials soon and may offer new hope for people with advanced Parkinson’s disease.
